Released May 10, 2022, before the open
10-Q filed May 10, 2022, 40 days after period end · 0001785530-22-000021
Q1 2022 · 10-Q
Revenue—
Net Income-$15.34M-$15.34M N/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.56-$0.56 N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$15,366,000N/M
Operating Cash Flow-$13,951,000N/M
Free Cash Flowderived-$13,979,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|
| Net Income | -$15.34M | -$7.44M | -$3.83M |
| EPS Diluted | -$0.56 | -$83.36 | -$4.58 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR